迈向预防人巨细胞病毒感染的预防性疫苗
Towards a Prophylactic Vaccine for the Prevention of HCMV Infection.
作者信息
Ligat Gaëtan, Alain Sophie, Hantz Sébastien
机构信息
Institut de Recherche sur les Maladies Virales et Hépatiques, Université de Strasbourg, 67000 Strasbourg, France.
INSERM, CHU Limoges, University of Limoges, RESINFIT, U1092, 87000 Limoges, France.
出版信息
Vaccines (Basel). 2021 Aug 29;9(9):968. doi: 10.3390/vaccines9090968.
Abstract
Human cytomegalovirus (HCMV) or human herpesvirus 5, is a ubiquitous human herpesvirus, which can cause severe disease in immunocompromised patients (AIDS patients and solid organ transplant or hematopoietic stem cell transplant recipients) [...].
摘要
人巨细胞病毒（HCMV）即人类疱疹病毒5型，是一种普遍存在的人类疱疹病毒，可在免疫功能低下的患者（艾滋病患者以及实体器官移植或造血干细胞移植受者）中引发严重疾病[……]
相似文献
1
Towards a Prophylactic Vaccine for the Prevention of HCMV Infection.迈向预防人巨细胞病毒感染的预防性疫苗
Vaccines (Basel). 2021 Aug 29;9(9):968. doi: 10.3390/vaccines9090968.
2
Herpesvirus infections in hematopoietic stem cell transplant recipients seropositive for human cytomegalovirus before transplantation.移植前对人巨细胞病毒血清学阳性的造血干细胞移植受者中的疱疹病毒感染
Int J Infect Dis. 2016 May;46:89-93. doi: 10.1016/j.ijid.2016.03.025. Epub 2016 Apr 4.
3
An overview of letermovir: a cytomegalovirus prophylactic option.来特莫韦概述：一种巨细胞病毒预防选择。
Expert Opin Pharmacother. 2019 Aug;20(12):1429-1438. doi: 10.1080/14656566.2019.1637418. Epub 2019 Jul 8.
4
Human cytomegalovirus (HCMV) infection/re-infection: development of a protective HCMV vaccine.人巨细胞病毒（HCMV）感染/再感染：一种保护性HCMV疫苗的研发
New Microbiol. 2019 Jan;42(1):1-20. Epub 2019 Jan 21.
5
Restriction of Human Cytomegalovirus Infection by Galectin-9.半乳糖凝集素-9抑制人巨细胞病毒感染。
J Virol. 2019 Jan 17;93(3). doi: 10.1128/JVI.01746-18. Print 2019 Feb 1.
6
Human Cytomegalovirus Latency and Reactivation in Allogeneic Hematopoietic Stem Cell Transplant Recipients.人巨细胞病毒在异基因造血干细胞移植受者中的潜伏与激活
Front Microbiol. 2019 May 28;10:1186. doi: 10.3389/fmicb.2019.01186. eCollection 2019.
7
Human cytomegalovirus seroprevalence and titres in solid organ transplant recipients and transplant donors in Seoul, South Korea.韩国首尔实体器官移植受者和供者的人巨细胞病毒血清流行率和滴度。
BMC Infect Dis. 2019 Nov 8;19(1):948. doi: 10.1186/s12879-019-4607-x.
8
9
Reconstitution of Human Cytomegalovirus-Specific CD4+ T Cells is Critical for Control of Virus Reactivation in Hematopoietic Stem Cell Transplant Recipients but Does Not Prevent Organ Infection.人巨细胞病毒特异性CD4+ T细胞的重建对于控制造血干细胞移植受者的病毒再激活至关重要，但不能预防器官感染。
Biol Blood Marrow Transplant. 2015 Dec;21(12):2192-2202. doi: 10.1016/j.bbmt.2015.08.002. Epub 2015 Aug 8.
10
Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital.采用 QuantiFERON-CMV assay 对爱尔兰医院的异基因造血干细胞移植受者进行人巨细胞病毒特异性 CD8(+) T 细胞反应的体外监测。
J Med Virol. 2010 Mar;82(3):433-40. doi: 10.1002/jmv.21727.
引用本文的文献
1
A promising endeavor against human cytomegalovirus: Predominant epitopes-based recombinant subunit vaccine RH.一项针对人巨细胞病毒的有前景的尝试：基于优势表位的重组亚单位疫苗RH。
Virulence. 2025 Dec;16(1):2497903. doi: 10.1080/21505594.2025.2497903. Epub 2025 May 5.
2
Challenges, Recent Advances and Perspectives in the Treatment of Human Cytomegalovirus Infections.人类巨细胞病毒感染治疗中的挑战、最新进展与展望
Trop Med Infect Dis. 2022 Dec 14;7(12):439. doi: 10.3390/tropicalmed7120439.
本文引用的文献
1
Cytomegalovirus Infection in Solid Organ and Hematopoietic Cell Transplantation: State of the Evidence.实体器官和造血细胞移植中的巨细胞病毒感染：证据状况
J Infect Dis. 2020 Mar 5;221(Suppl 1):S23-S31. doi: 10.1093/infdis/jiz454.
2
Advances in the Development of Therapeutics for Cytomegalovirus Infections.巨细胞病毒感染治疗方法的进展
J Infect Dis. 2020 Mar 5;221(Suppl 1):S32-S44. doi: 10.1093/infdis/jiz493.
3
Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance.巨细胞病毒抗病毒药物耐药性的基因诊断进展。
Antiviral Res. 2020 Apr;176:104711. doi: 10.1016/j.antiviral.2020.104711. Epub 2020 Jan 12.
4
Highlighting of a LAGLIDADG and a Zing Finger Motifs Located in the pUL56 Sequence Crucial for HCMV Replication.突出 pUL56 序列中对 HCMV 复制至关重要的 LAGLIDADG 和 Zing 指模。
Viruses. 2019 Nov 26;11(12):1093. doi: 10.3390/v11121093.
5
Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity.多抗原性人巨细胞病毒 mRNA 疫苗可诱导强烈的体液和细胞介导免疫。
Vaccine. 2018 Mar 14;36(12):1689-1699. doi: 10.1016/j.vaccine.2018.01.029. Epub 2018 Feb 15.
6
The human cytomegalovirus terminase complex as an antiviral target: a close-up view.人类巨细胞病毒终止酶复合物作为抗病毒靶点：特写。
FEMS Microbiol Rev. 2018 Mar 1;42(2):137-145. doi: 10.1093/femsre/fuy004.
7
A Phase 1 Study of 4 Live, Recombinant Human Cytomegalovirus Towne/Toledo Chimera Vaccines in Cytomegalovirus-Seronegative Men.4种重组人巨细胞病毒Towne/Toledo嵌合活疫苗在巨细胞病毒血清学阴性男性中的1期研究。
J Infect Dis. 2016 Nov 1;214(9):1341-1348. doi: 10.1093/infdis/jiw365. Epub 2016 Aug 11.
8
Self-amplifying mRNA vaccines.自我扩增mRNA疫苗。
Adv Genet. 2015;89:179-233. doi: 10.1016/bs.adgen.2014.10.005. Epub 2014 Dec 4.
9
Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next?开发针对先天性巨细胞病毒（CMV）感染的疫苗：我们从动物模型中学到了什么？接下来我们该何去何从？
Future Virol. 2013 Dec;8(12):1161-1182. doi: 10.2217/fvl.13.106.
10
Nonviral delivery of self-amplifying RNA vaccines.非病毒载体递送自我扩增 RNA 疫苗。
Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14604-9. doi: 10.1073/pnas.1209367109. Epub 2012 Aug 20.
Zotero 插件